Related Experiment Video
Updated: Aug 8, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A Donehower1, Thierry Soussi2, Anil Korkut3
1Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
The TP53 tumor suppressor gene is frequently mutated in human cancers. An analysis of five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer Genome Atlas (TCGA) enables comprehensive assessment of p53 pathway involvement in these cancers. More than 91% of TP53-mutant cancers exhibit second allele loss by mutation, chromosomal deletion, or copy-neutral loss of heterozygosity. TP53 mutations are associated with enhanced chromosomal instability, including increased amplification of oncogenes and deep deletion of tumor suppressor genes. Tumors with TP53 mutations differ from their non-mutated counterparts in RNA, miRNA, and protein expression patterns, with mutant TP53 tumors displaying enhanced expression of cell cycle progression genes and proteins. A mutant TP53 RNA expression signature shows significant correlation with reduced survival in 11 cancer types. Thus, TP53 mutation has profound effects on tumor cell genomic structure, expression, and clinical outlook.
Insights
TP53 mutations are common in cancers and lead to genomic instability and altered gene expression. These changes in the TP53 pathway significantly impact tumor development and reduce patient survival across multiple cancer types.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- The TP53 tumor suppressor gene is frequently altered in human cancers.
- Understanding the p53 pathway's role is crucial for cancer research.
Purpose of the Study:
- To comprehensively assess p53 pathway involvement in 32 cancer types using TCGA data.
- To investigate the genomic and expression consequences of TP53 mutations.
Main Methods:
- Analysis of 10,225 patient samples across 32 cancer types from five data platforms.
- Examination of TP53 mutation status, second allele loss, and chromosomal instability.
- Assessment of RNA, miRNA, and protein expression patterns in tumors with and without TP53 mutations.
Main Results:
- Over 91% of TP53-mutant cancers showed second allele loss.
- TP53 mutations correlated with increased chromosomal instability, oncogene amplification, and tumor suppressor gene deletion.
- Mutant TP53 tumors exhibited distinct expression profiles, including enhanced cell cycle gene and protein expression.
- A mutant TP53 RNA expression signature was linked to reduced survival in 11 cancer types.
Conclusions:
- TP53 mutations profoundly impact tumor cell genomic structure and expression.
- TP53 mutation status is a significant factor in cancer development and clinical outcome.
- Targeting the p53 pathway may offer therapeutic strategies for various cancers.
More Related Videos
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...